Study: Amgen's Xgeva to become top-prescribed drug in 2012
The drug is indicated for the prevention of skeletal-related events (SREs) in prostate cancer patients. The study also examines the reimbursement climate for existing and anticipated SRE-prevention therapies.
Although Novartis' Zometa (zoledronic acid) drug will likely remain the top-prescribed drug for preventing SREs in breast and lung cancer patients, physicians in the study believe Xgeva's share will more than double for these indications over the next 12 months.
Hannah Slater, lead researcher on the study, said: â€œCurrently, Zometa maintains a dominant position in preventing skeletal-related events in prostate, breast, and lung cancer patients, but our data clearly show that Xgeva has already obtained significant penetration in the market.
â€œAssuming physicians and patients continue to be happy with Xgeva, the product is on track to meet pre-launch expectations and become the top-prescribed drug in this class within the next few years.â€
The study shows that physicians in ITG's Oncology Panel are already prescribing Xgeva for more than 10 percent of their prostate, breast, and lung cancer patients who have bone metastases.
Physicians in the panel did acknowledge Xgeva's relatively high cost and also expressed concerns about risks associated with osteonecrosis of the jaw, but they generally expressed enthusiasm for Xgeva's increased efficacy, its subcutaneous route of administration, and its convenient dosing.
Not only do they plan to initiate more patients on Xgeva as a first-line therapy, physicians also expect to switch a significant number of patients from Zometa to Xgeva over the next year.
Amgen's denosumab first received approval for the treatment of osteoporosis in June 2010 under the trade name, Prolia, and it received approval for a second indication in November 2010 under the trade name, Xgeva, for the prevention of SREs in patients with bone metastases from solid tumors.
Amgen has since submitted a supplemental Biologics License Application (sBLA) to the FDA to further expand the indication for Xgeva to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases.
According to ITG, launch of Xgeva includes analysis of a targeted survey of 50 oncologists and 50 urologists, and 10 in-depth telephone interviews with pharmacy directors at major managed care organizations.
Have your say and discuss with your peers on the InfoGrok community.